5 курс / Психиатрия и наркология для детей и взрослых (доп.) / Клиническая_психофармакогенетика_Р_Ф_Насырова,_Н_Г
.pdfГлава 8. ФАРМАКОГЕНЕТИКА ПРОТИВОЭПИЛЕПТИЧЕСКИХ ПРЕПАРАТОВ |
|
8.2. Фармакогенетика карбамазепина |
||||
epine suppositories: a pharmacokinetic and clinical study in |
НИПНИ им. В.М. Бехтерева, 2015. – 272. ISBN 978-5- |
|||||
children with epilepsy // J Child Neurol. 1995; 10(2):114–117. |
7452-0020-5. |
|||||
doi:10.1177/088307389501000209. |
|
|
|
46.\ |
Potschka H., Fedrowitz M., Loscher W. P-glyco- |
|
31.\ Miles M.V., Lawless S.T., Tennison M.B. et al. Rapid |
protein and multidrug resistance-associated protein are in- |
|||||
loadingofcriticallyillpatientswithcarbamazepinesuspension |
volved in the regulation of extracellular levels of the major |
|||||
// Pediatrics. 1990; 86(2):263–266. doi:10.1097/00008506- |
antiepileptic drug carbamazepine in the brain // NeuroRe- |
|||||
199610000-00103. |
|
|
|
port. 2001; 12(16):3557–3560. doi:10.1097/00001756- |
||
32.\ Milovanovic J.R., Jankovic S.M. Factors influenc- |
200111160-00037. |
|||||
ing carbamazepine pharmacokinetics in children and adults: |
47. Аксенова М.Г., Качалин Е.Ю., Бурд С.Г., Авакян |
|||||
population pharmacokinetic analysis // Int J Clin Pharmacol |
Г.Н., Бадалян О.Л., Савенков А.А. и другие. Связь |
|||||
Ther. 2011; 49(7):428–436. doi:10.5414/cp201517. |
|
полиморфизма С3435 гена MDR1 с эффективностью |
||||
33.\ |
Carlsson K.C., Hoem N.O., Glauser T., Vinks |
действия карбамазепинов // Медицинская генетика. |
||||
A.A. Development of a population pharmacokinetic |
2007. № 6 (10). С. 39–41. |
|||||
model for carbamazepine based on sparse therapeu- |
48.\ Emich-Widera E., Likus W., Kazek B. et al. CYP3A5*3 |
|||||
tic monitoring data from pediatric patients with epilepsy |
and C3435T MDR1 polymorphisms in prognostication of |
|||||
// Clin Ther. 2005; 27(5):618–626. doi:10.1016/j.clin- |
drug-resistant epilepsy in children and adolescents // Biomed |
|||||
thera.2005.05.001. |
|
|
|
Res Int. 2013; 2013:526837. doi:10.1155/2013/526837. |
||
34.\ Summers B., Summers R.S. Carbamazepine clear- |
49.\ Kim W.J., Lee J.H., Yi J. et al. A nonsynonymous |
|||||
ance in paediatric epilepsy patients. Influence of body mass, |
variation in MRP2/ABCC2 is associated with neurological ad- |
|||||
dose, sex and co-medication // Clin Pharmacokinet. 1989; |
verse drug reactions of carbamazepine in patients with ep- |
|||||
17(3):208–216. doi:10.2165/00003088-198917030-00006. |
ilepsy // Pharmacogenet Genomics. 2010; 20(4):249–256. |
|||||
35.\ |
Hartley R., Forsythe W.I., McLain |
B. |
et al. |
doi.:10.1097/fpc.0b013e328338073a. |
||
Daily variations in steady-state |
plasma |
concentra- |
50.\ |
Pelkonen O., Myllynen P., Taavitsainen P. et al. |
||
tions of |
carbamazepine and its metabolites |
in |
epilep- |
Carbamazepine: a ‘blind’ assessment of CVP-associat- |
||
tic children // Clin Pharmacokinet. 1991; 20(3):237–246. |
ed metabolism and interactions in human liver-derived |
|||||
doi:10.2165/00003088-199120030-00005. |
|
|
in vitro systems // Xenobiotica. 2001; 31(6):321–343. |
|||
36.\ |
Paxton J.W., Aman M.G., Werry J.S. Fluctuations |
doi:10.1080/00498250110055479. |
||||
in salivary carbamazepine and carbamazepine-10,11-epox- |
51.\ |
Thorn C.F., Leckband S.G., Kelsoe J. et al. |
||||
ide concentrations during the day in epileptic children. Ep- |
PharmGKB summary: carbamazepine pathway // Pharma- |
|||||
ilepsia. 1983; 24(6):716–724. doi:10.1111/j.1528-1157.1983. |
cogenet Genomics. 2011; 21(12):906–910. doi:10.1097/fpc. |
|||||
tb04634.x. |
|
|
|
0b013e328348c6f2. |
||
37.\ Emich-Widera E., Likus W., Kazek B. et al. CYP3A5*3 |
52.\ |
Djordjevic N., Jankovic S.M., Milovanovic J.R. |
||||
and C3435T MDR1 polymorphisms in prognostication of |
Pharmacokinetics and pharmacogenetics of carbamaze- |
|||||
drug-resistant epilepsy in children and adolescents // Biomed |
pine in children // European Journal of Drug Metabolism and |
|||||
Res Int. 2013; 2013:526837. doi:10.1155/2013/526837. |
Pharmacokinetics. 2017; 42(5):729-744. |
|||||
38.\ |
Ufer M., von Stulpnagel C., Muhle H. et al. Im- |
53.\ |
Sadee W. The relevance of “missing heritabili- |
|||
pact of ABCC2 genotype on antiepileptic drug response |
ty” in pharmacogenomics // Clin Pharmacol Ther. 2012; |
|||||
in Caucasian patients with childhood epilepsy // Pharma- |
92(4):428–430. |
|||||
cogenet Genomics. 2011; 21(10):624–630. doi:10.1097/ |
54.\ |
Zanger U.M., Schwab M. Cytochrome P450 en- |
||||
fpc.0b013e3283498131. |
|
|
|
zymes in drug metabolism: regulation of gene expres- |
||
39.\ Pearce R.E., Lu W., Wang Y.Q., Uetrecht J.P., Correia |
sion, enzyme activities, and impact of genetic variation |
|||||
M.A., Leeder J.S. Pathways of сarbamazepine bioactivation |
// Pharmacol Ther. 2013; 138:103–141. doi: 10.1016/j. |
|||||
in vitro. III. The role of human cytochrome P450 enzymes in |
pharmthera.2012.12.007. |
|||||
the formation of 2, 3-dihydroxycarbamazepine // Drug Me- |
55.\ Maekawa K., Yoshimura T., Saito Y., Fujimura Y., Ao- |
|||||
tabolism and Disposition August 2008, 36 (8) 1637-1649. |
hara F., Emoto C., Iwasaki K.et al; The fate of foreign com- |
|||||
doi:10.1124/dmd.107.019562. |
|
|
|
pounds in biological systems; 2009. PMID: 19255940 doi: |
||
40.\ |
Kerr B.M., Thummel K.E., Wurden C.J. et al. |
10.1080/00498250802617746. |
||||
Human liver carbamazepine metabolism. Role of CY- |
56.\ Maekawa K., Harakawa N., Yoshimura., Kim S.R., |
|||||
P3A4 and CYP2C8 in 10,11-epoxide formation // Biochem |
FujimuraY., Aohara F., Sai K. et al. In Drug metabolism and |
|||||
Pharmacol. 1994; 47(11):1969–1979. doi:10.1016/0006- |
disposition: the biological fate of chemicals; 2010. doi: |
|||||
2952(94)90071-x. |
|
|
|
10.1124/dmd.110.034140. |
||
41.\ |
Pelkonen O., Myllynen P., Taavitsainen P. et al. |
57.\ Hustert E., Haberl M., Burk O. et al. The genetic de- |
||||
Carbamazepine: a ‘blind’ assessment of CVP-associat- |
terminants of the CYP3A5 polymorphism // Pharmacogenet- |
|||||
ed metabolism and interactions in |
human liver-derived |
ics. 2001; 11:773–779. |
||||
in vitro systems // Xenobiotica. 2001; 31(6):321–343. |
58.\ Kuehl P., Zhang J., Lin Y. et al. Sequence diversity in |
|||||
doi:10.1080/00498250110055479. |
|
|
|
CYP3A promoters and characterization of the genetic basis |
||
42.\ Kang P., Liao M., Wester M.R. et al. CYP3A4-Me- |
of polymorphic CYP3A5 expression // Nat Genet. 2001; 27: |
|||||
diated carbamazepine (CBZ) metabolism: formation of a |
383–391. doi: 10.1038/86882. |
|||||
covalent CBZ-CYP3A4 adduct and alteration of the enzyme |
59.\ Saruwatari J., Yoshida S., Tsuda Y. et al. Pregnane |
|||||
kinetic profile // Drug Metab Dispos. 2008; 36(3):490–499. |
X receptor and hepatocyte nuclear factor 4alpha polymor- |
|||||
doi:10.1124/dmd.107.016501. |
|
|
|
phisms are cooperatively associated with carbamazepine au- |
||
43.\ |
Shakya G., Malla S., Shakya K.N., Shrestha R. |
toinduction // Pharmacogenet Genomics. 2014; 24(3):162– |
||||
Therapeutic drug monitoring of antiepileptic drugs // JNMA |
171. doi: 10.1097/FPC.0000000000000030. |
|||||
J Nepal Med Assoc. 2008; 47(171):94-97. doi:10.31729/ |
60.\ |
Dragas-Milovanovic D., Radosavljevic I., Radova- |
||||
jnma.294. |
|
|
|
novic M. et al. CYP3A5 polymorphism in Serbian paediatric |
||
44.\ Дмитренко Д.В., Шнайдер Н.А., Бочанова Е.Н., |
epileptic patients on carbamazepine treatment // SJECR. |
|||||
Артюхов И.П., Зырянов С.К. и другие. Терапевтический |
2015; 16(2):93–99. doi: 10.1515/SJECR-2015-0012. |
|||||
лекарственный мониторинг в лечении эпилепсии // Врач. |
61.\ |
Pearce R.E., Vakkalagadda G.R., Leeder J.S. |
||||
2017. № 1. С. 81–83. |
|
|
|
Pathways of carbamazepine bioactivation in vitro I. Char- |
||
45.\ Насырова Р.Ф., Иванов М.В., Незнанов Н.Г. |
acterization of human cytochromes P450 responsible for |
|||||
Введение в психофармакогенетику. – СПб.: Изд-во СПб |
the formation of 2- and 3-hydroxylated metabolites // |
|||||
|
|
|
|
|
|
285 |
Рекомендовано к покупке и изучению сайтом МедУнивер - https://meduniver.com/
Глава 8. ФАРМАКОГЕНЕТИКА ПРОТИВОЭПИЛЕПТИЧЕСКИХ ПРЕПАРАТОВ |
|
8.2. Фармакогенетика карбамазепина |
||
92.\ Khor A.H., Lim K.S., Tan C.T., Wong S.M., Ng C.C. |
103.\ Amstutz U., Ross C.J., Castro-Pastrana L.I., Rie- |
|||
HLA-B*15:02 association with carbamazepine-induced Ste- |
der M.J., Shear N.H., Hayden M.R., Carleton B.C. CPNDS |
|||
vens-Johnson syndrome and toxic epidermal necrolysis in an |
Consortium. HLA-A 31:01 and HLA-B 15:02 as genetic |
|||
Indian population: a pooled-data analysis and meta-analysis |
markers for carbamazepine hypersensitivity in children // |
|||
// Epilepsia. 2014; 55(11):e120-4. doi: 10.1111/epi.12802. |
Clin Pharmacol Ther. 2013; 94(1):142-149. doi: 10.1038/ |
|||
93.\ |
Leckband S.G., Kelsoe J.R., Dunnenberger H.M., |
clpt.2013.55. |
|
|
George A.L. Jr., Tran E., Berger R., Müller D.J. et al. Clini- |
104.\ McCormack M., Alfirevic A., Bourgeois S., Far- |
|||
cal Pharmacogenetics Implementation Consortium. Clinical |
rell J.J., Kasperavičiūtė D., Carrington M., Sills G.J. et al. |
|||
Pharmacogenetics Implementation Consortium guidelines for |
HLA-A*3101 and carbamazepine-induced hypersensitivity |
|||
HLA-B genotype and carbamazepine dosing // Clin Pharma- |
reactions in Europeans // N Engl J Med. 2011; 364(12):1134- |
|||
col Ther. 2013; 94(3):324-328. doi: 10.1038/clpt.2013.103. |
1143. doi: 10.1056/NEJMoa1013297. |
|
||
94.\ Chen P., Lin J.J., Lu C.S., Ong C.T., Hsieh P.F., Yang |
105.\ Genin E., Chen D.P., Hung S.I., Sekula P., Schum- |
|||
C.C., Tai C.T. et al.Taiwan SJS Consortium. Carbamaze- |
acher M., Chang P.Y., Tsai S.H. et al. HLA-A*31:01 and dif- |
|||
pine-induced toxic effects and HLA-B*1502 screening in Tai- |
ferent types of carbamazepine-induced severe cutaneous |
|||
wan // N Engl J Med. 2011; 364(12):1126-1133. doi: 10.1056/ |
adverse reactions: an international study and meta-analysis |
|||
NEJMoa1009717. |
// Pharmacogenomics J. 2014; 14(3):281-288. doi: 10.1038/ |
|||
95.\ |
Puangpetch A., Koomdee N., Chamnanphol M., |
tpj.2013.40. |
|
|
Jantararoungtong T., Santon S., Prommas S., Hongkaew Y. et |
106.\ Kaniwa N., Saito Y., Aihara M., Matsunaga K., |
|||
al. HLA-B allele and haplotype diversity among Thai patients |
Tohkin M., Kurose K., Furuya H. et al. JSAR research group. |
|||
identified by PCR-SSOP: evidence for high risk of drug-in- |
HLA-B*1511 is a risk factor for carbamazepine-induced Ste- |
|||
duced hypersensitivity // Front Genet. 2015; 5: 478. doi: |
vens-Johnson syndrome and toxic epidermal necrolysis in |
|||
10.3389/fgene.2014.00478. |
Japanese patients // Epilepsia. 2010; 51(12):2461-2465. doi: |
|||
96.\ Alfirevic A., Jorgensen A.L., Williamson P.R., |
10.1111/j.1528-1167.2010.02766.x. |
|
||
Chadwick D.W., Park B.K., Pirmohamed M. HLA-B lo- |
107.\ Kim S.H., Lee K.W., Song W.J., Kim S.H., Jee Y.K., |
|||
cus in Caucasian patients with carbamazepine hyper- |
Lee S.M., Kang H.R., et al. Adverse Drug Reaction Research |
|||
sensitivity // Pharmacogenomics. 2006; 7(6):813-818. |
Group in Korea. Carbamazepine-induced severe cutane- |
|||
doi:10.2217/14622416.7.6.813. |
ous adverse reactions and HLA genotypes in Koreans // |
|||
97.\ Lonjou C., Borot N., Sekula P., Ledger N., Thomas |
Epilepsy Res. 2011; 97(1-2):190-197. doi: 10.1016/j.eplep- |
|||
L., Halevy S., Naldi L. et al. RegiSCAR study group. A Europe- |
syres.2011.08.010. |
|
|
|
an study of HLA-B in Stevens-Johnson syndrome and toxic |
108.\ Leckband S.G., Kelsoe J.R., Dunnenberger H.M., |
|||
epidermal necrolysis related to five high-risk drugs // Phar- |
George A.L. Jr., Tran E., Berger R., Müller D.J. et al. Clini- |
|||
macogenet Genomics. 2008; 18(2):99-107. doi: 10.1097/ |
cal Pharmacogenetics Implementation Consortium. Clini- |
|||
FPC.0b013e3282f3ef9c. |
cal Pharmacogenetics Implementation Consortium guide- |
|||
98.\ Chen Z., Liew D., Kwan P. Effects of a HLA-B*15:02 |
lines for HLA-B genotype and carbamazepine dosing // |
|||
screening policy on antiepileptic drug use and severe skin re- |
Clin Pharmacol Ther. 2013; 94(3):324-328. doi: 10.1038/ |
|||
actions // Neurology. 2014; 83(22):2077-2084. doi: 10.1212/ |
clpt.2013.103. |
|
|
|
WNL.0000000000001034. |
109.\ Holland K.D., Kearney J.A., Glauser T.A., Buck G., |
|||
99.\ Hung S.I., Chung W.H., Jee S.H., Chen W.C., Chang |
Keddache M., Blankston J.R., Glaaser I.W. et al. Mutation of |
|||
Y.T., Lee W.R., Hu S.L. Genetic susceptibility to carbamaze- |
sodium channel SCN3A in a patient with cryptogenic pediat- |
|||
pine-induced cutaneous adverse drug reactions // Pharma- |
ric partial epilepsy // Neurosci Lett. 2008; 433(1):65–70. doi: |
|||
cogenet Genomics. 2006; 16(4):297-306. doi: 10.1097/01. |
10.1016/j.neulet.2007.12.064. |
|
|
|
fpc.0000199500.46842.4a. |
110.\ Abe T., Seo T., Ishitsu T., Nakagawa T., Hori M., Na- |
|||
100.\ Mizumoto K., Sumikawa Y., Niihara H., Morita E. |
kagawa K. Association between SCN1A polymorphism and |
|||
Case of carbamazepine-induced hypersensitivity syndrome |
carbamazepine-resistant epilepsy // British Journal of Clini- |
|||
associated with human leukocyte antigen-A*3101 // J Der- |
cal Pharmacology 2008; 66(2):304-307. doi:10.1111/j.1365- |
|||
matol. 2012; 39(9):791-792. |
2125.2008.03203.x. |
|
|
|
101.\ Ozeki T., Mushiroda T., Yowang A., Takahashi A., |
111.\ Daci A., Beretta G., Vilasaliu D., Shala A., Govori V., |
|||
Kubo M., Shirakata Y., Ikezawa Z. et al. Genome-wide asso- |
Norata G.D., Krasniqi S. Polymorphic variants of SCN1A and |
|||
ciation study identifies HLA-A*3101 allele as a genetic risk |
EPHX1 influence plasma carbamazepine concentration, me- |
|||
factor for carbamazepine-induced cutaneous adverse drug |
tabolism and pharmacoresistance in a population of Koso- |
|||
reactions in Japanese population // Hum Mol Genet. 2011; |
var Albanian epileptic patients// PLOS.2015; 10 (11). doi: |
|||
20(5):1034-1041. doi: 10.1093/hmg/ddq537. |
10.1371/journal.pone.0142408. |
|
||
102.\ Niihara H., Kakamu T., Fujita Y., Kaneko S., Morita E. |
112. Авакян Г.Н., Бурд С.Г. Современный взгляд на |
|||
HLA-A31 strongly associates with carbamazepine-induced |
применение пролонгированной формы карбамазепина |
|||
adverse drug reactions but not with carbamazepine-in- |
// Эпилепсия и пароксизмальные состояния. 2012. № 4 |
|||
duced lymphocyte proliferation in a Japanese population |
(2). С. 67–71. |
|
|
|
// J Dermatol. 2012; 39(7):594-601. doi: 10.1111/j.1346- |
113.\ Государственный |
реестр |
лекарственных |
|
8138.2011.01457.x. |
средств. https://grls.rosminzdrav.ru |
|
287
Рекомендовано к покупке и изучению сайтом МедУнивер - https://meduniver.com/